Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Display:
EPIDEMIC! not that one, the other one.
Advocacy blitz targets Medicare coverage of obesity treatment
Advocates say the drug carveout stems from lingering cultural stigma around obesity and a societal view that weight problems are a personal failure. Obesity was recognized as a disease by the American Medical Association in 2013, and the incidence of obesity has grown over time. The bipartisan bill, sponsored by Ron Kind, D-Wis., in the House and Thomas R. Carper, D-Del., in the Senate, has 117 co-sponsors between the two chambers.

About 42 percent of U.S. adults were considered obese in 2018, according to the Centers for Disease Control and Prevention. Obesity is a risk factor for many other top chronic diseases, including diabetes, heart disease and stroke. Annual obesity-related medical costs are estimated at $147 billion to $210 billion.
[...]
The drug industry is also deeply invested in the obesity field, and it stands to gain access to the $102 billion Part D drug market if the Medicare ban is lifted. Insulin and weight loss drug manufacturers like Novo Nordisk and Eli Lilly donate cash to many advocacy groups, politicians and medical research projects associated with obesity treatments, including Kind and Carper. ... "Senator Carper's Treat and Reduce Obesity Act has a robust group of bipartisan cosponsors and widespread support from groups representing American families struggling with obesity," a spokesman for Carper said. "UNLEASHING federal Medicare dollars for treatments against obesity would help millions of Americans lead longer and healthier lives."

reference
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
-- Why Was Belviq Recalled?
FDA | Questions and Answers about FDA's Initiative Against Contaminated Weight Loss Products
-- Why was Fen-Phen recalled?
Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications
novel substituents into the fentanyl structure a/o 2014
by Cat on Fri Dec 3rd, 2021 at 06:23:07 PM EST
[ Parent ]
Hagan, "E66.01 and Our My Culture of Shame," 11 Dec
The request for a nonformulary drug required an associated International Classification of Diseases, 10th Revision (ICD-10) diagnosis. Groaning as I typed "obesity," I knew the search result I would select: "morbid (severe) obesity due to excess calories" (E66.01). Although "other obesity" (E66.8) and "obesity, unspecified" (E66.9) were also options, they lacked a more precise obesity classification, and I worried that they might not be convincing enough to justify an authorization for an expensive drug ["an injectable glucagon-like peptide 1 (GLP-1) analogue"]. Resigning myself to choose E66.01, I could almost see the contempt for the patient dripping off the screen. What was the "due to" modifier adding? If an explanation was needed, why not
diabetes mellitus?
"severe obesity, due to long-term exposure to an environment full of nutrient-poor and calorie-dense foods, along with activity-sparing technology, leading to reduced daily energy expenditure, with resultant permanent dysregulation of the part [?] of the neuroendocrine system controlling energy balance"?
[...]
As a clinician who had known him for years and struggled with obesity throughout my own life, surely I had fared better in conveying empathy for his struggle and had added some nuance to the discussion?
"the part" of "activity-sparing technology"
Cohen and Spiegelman, "Cell biology of fat storage" (2016)
GLP-1 agonists: Diabetes drugs and weight loss
Diabetes drugs in the GLP-1 [receptor] agonists class include:

  • Dulaglutide (Trulicity), taken by injection weekly
  • Exenatide extended release (Bydureon), taken by injection weekly
  • Exenatide (Byetta), taken by injection twice daily
  • Semaglutide (Ozempic), taken by injection weekly
  • Semaglutide (Rybelsus), taken by mouth once daily
  • Liraglutide (Victoza), taken by injection daily
  • Lixisenatide (Adlyxin), taken by injection daily
by Cat on Sun Dec 12th, 2021 at 02:06:14 AM EST
[ Parent ]
1-800-GET-THIN owner found guilty in $250 million fraud trial
The sleep studies were used to find a second reason, a so-called [!] comorbidity [AKA disease], to justify the lap-band procedure [AKA bariatric surgery] for obese patients.
by Cat on Fri Dec 17th, 2021 at 05:07:56 PM EST
[ Parent ]

Display:

Top Diaries

Occasional Series